Gilead Sciences Inc (NASDAQ:GILD) Sentiment Falls to 0.8, Despite

May 16, 2018 - By Patrick Harkless

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate Logo

“Big money” Positions

In Q4 2017 Gilead Sciences Inc (NASDAQ:GILD) big money sentiment decreased to 0.8, according to SEC filings. That’s down -0.23, from 2017Q3’s 1.03. 515 investment professionals opened new and increased positions, while 640 cut down and sold equity positions in Gilead Sciences Inc so the sentiment turned negative. These funds own 972.68 million shares, that’s up from 957.62 million shares in 2017Q3. Funds holding Gilead Sciences Inc in top 10 changed to 40 from 68 for a decrease of 28. In total 95 funds closed positions, 545 reduced and 411 increased. Also 104 funds bought new Gilead Sciences Inc stakes.

Significant Gilead Sciences Inc Investors

Healthcare Value Capital Llc owns 75,000 shares in Gilead Sciences Inc as of Q4 2017. Gilead Sciences Inc’s shareholder Krensavage Asset Management Llc owns 478,053 shares as of Q4 2017. Underhill Investment Management Llc reported 204,700 shares. The Massachusetts-based fund Tekla Capital Management Llc have invested about 6.96% of the active investment manager’s stock portfolio in Gilead Sciences Inc. The Alabama-based fund Cabot looks positive on Gilead Sciences Inc, having 137,230 shares.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East.The company has $87.82 billion market cap. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.25.69 is the P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

GILD is touching $67.54 during the last trading session, after increased 0.82%.Gilead Sciences, Inc. has volume of 4.26 million shares. Since May 16, 2017 GILD has risen 9.79% and is uptrending. The stock underperformed the S&P500 by 1.76%.

Earnings report for Gilead Sciences, Inc. (NASDAQ:GILD) is expected on July, 25., RTT reports. Last year’s earnings per share was $2.51, while now analysts expect change of 43.03 % down from current $1.43 earnings per share. If GILD’s EPS is $1.43 the profit will hit $1.86B for 11.81 P/E. Wall Street sees 4.38 % EPS growth as of July, 25.

10,068 were accumulated by Argent Trust. State Of Tennessee Treasury Department, a Tennessee-based fund reported 337,927 shs. Ingalls & Snyder Ltd Liability Corporation accumulated 181,230 shs. Piedmont Advisors Limited Liability Company has invested 0.41% in Gilead Sciences, Inc. (NASDAQ:GILD). Aldebaran holds 17,855 shs. Japan-based Tokio Marine Asset Mgmt Co Ltd has invested 0.78% in Gilead Sciences, Inc. (NASDAQ:GILD). Fil holds 2.09 million shs. Meridian Inv Counsel reported 27,757 shs or 1.09% of all its holdings. Meeder Asset Mngmt invested in 76,176 shs or 0.46% of the stock. Natixis Asset Mngmt, France-based fund reported 77,730 shs. National Bank Of Hawaii reported 0.25% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Mycio Wealth Prtnrs Limited Liability has invested 0.08% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Switzerland-based Banque Pictet Cie has invested 0.2% in Gilead Sciences, Inc. (NASDAQ:GILD). Nj State Employees Deferred Compensation Plan invested 0.5% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Ionic Limited Liability Company holds 0.07% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD) for 24,312 shs.

Gilead Sciences, Inc. registered $44.80 million net activity with 0 buys and 22 sales since January 2, 2018. Cogan John Francis had sold 5,833 shs worth $437,588 on Friday, March 23. On Tuesday, January 16 Meyers James R also sold $8.02 million worth of Gilead Sciences, Inc. (NASDAQ:GILD). Another trade for 50,000 shs valued at $3.66 million was made by MARTIN JOHN C on Monday, April 2. Alton Gregg H sold $1.18 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 14,435 shs on Tuesday, February 20. 60,000 shs were sold by WILSON GAYLE E, worth $4.68 million.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

In total 14 analysts cover Gilead Sciences (NASDAQ:GILD). “Buy” rating has 8, “Sell” are 0, while 6 are “Hold”. (NASDAQ:GILD) has 57% bullish analysts. 24 are the (NASDAQ:GILD)’s ratings reports on 16 May 2018 according to StockzIntelligence Inc. On Wednesday, February 7 the firm has “Neutral” rating given by Bank of America. On Wednesday, December 20 the rating was downgraded by Credit Suisse to “Neutral”. On Tuesday, February 6 the stock has “Buy” rating by Maxim Group. In Thursday, February 22 report Leerink Swann maintained the stock with “Hold” rating. The stock rating was upgraded by Citigroup to “Buy” on Tuesday, January 30. On Wednesday, February 7 Leerink Swann maintained the shares of GILD in report with “Market Perform” rating. On Thursday, November 30 the firm earned “Buy” rating by Maxim Group. On Tuesday, January 2 the stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by BMO Capital Markets. On Wednesday, February 7 the firm has “Buy” rating by RBC Capital Markets given. In Wednesday, May 2 report Leerink Swann maintained the stock with “Hold” rating.

For more Gilead Sciences, Inc. (NASDAQ:GILD) news posted briefly go to: Seekingalpha.com, Bizjournals.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Kite Pharma continues buildout for cell therapy manufacture” posted on May 15, 2018, “2 big Bay Area companies look to map, tackle inflammatory diseases” on April 30, 2018, “FDA OKs expanded use for Gilead’s Truvada” with a publish date: May 15, 2018, “Gilead: What A Disaster” and the last “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” with publication date: May 15, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: